Physician profile
Parth Shah
NPI 1992069264
$776.12
in general payments reported to CMS, 2019-2025
15 companies · $509 in 2025
The $509 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $53.72 · 2021: $80.18 · 2022: $16.85 · 2023: $77.19 · 2024: $38.85 · 2025: $509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $625.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $174.34 | 2025 | |
| Medtronic, INC. | $135.67 | 2025 | Signia |
| Stryker Corporation | $87.92 | 2025 | Scopis Ent |
| Sight Sciences, INC. | $80.18 | 2021 | |
| Impulse Dynamics (USA) INC. | $58.39 | 2025 | Optimizer |
| Boston Scientific Corporation | $53.72 | 2020 | |
| Abbvie INC. | $45.82 | 2023-2025 | Linzess, Creon, Viberzi |
| Argon Medical Devices, INC. | $24.52 | 2024 | Clot Management |
| Kerecis Limited | $17.52 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Evofem Biosciences, INC. | $17.42 | 2025 | Phexxi, Solosec, Phexx |
| Glaxosmithkline, LLC. | $17.00 | 2023 | Shingrix |
| Vivus LLC | $17.00 | 2023 | Qsymia |
| Abbott Laboratories | $16.85 | 2022 | |
| Currax Pharmaceuticals LLC | $15.44 | 2023 | Contrave |
| Pfizer INC. | $14.33 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parth Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.